Canada markets open in 12 minutes

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3100+0.0100 (+0.30%)
At close: 04:00PM EDT
3.3200 +0.01 (+0.30%)
Pre-Market: 09:17AM EDT

Geron Corporation

919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees141

Key Executives

NameTitlePayExercisedYear Born
Dr. John A. Scarlett M.D.Chairman of the Board, President & CEO1.53MN/A1951
Dr. Andrew J. Grethlein Ph.D.Executive VP & COO847.2kN/A1964
Ms. Michelle J. RobertsonExecutive VP, CFO, Treasurer and Principal Financial & Accounting OfficerN/AN/A1968
Ms. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryN/AN/AN/A
Ms. Shannon OdamSenior VP & Chief People OfficerN/AN/A1975
Ms. Melissa A. Kelly BehrsExecutive VP of Business Operations & Chief Alliance Officer753.22kN/A1964
Mr. Anil KapurExecutive VP of Corporate Strategy & Chief Commercial Officer654.89kN/A1971
Mr. Edward E. KovalExecutive VP & Chief Business OfficerN/AN/A1962
Dr. Faye Feller M.D.Executive VP & Chief Medical OfficerN/AN/A1983
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Corporate Governance

Geron Corporation’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.